Immersive virtual reality (IVR), as a non-pharmacologic, non-invasive approach to managing symptoms in cancer patients, when combined with standard pharmacologic care was discussed at the ESMO AI & Digital Oncology Congress, held in Berlin, November 16-18, 2026. Following 3 20-minute IVR sessions, administered 2 hours and 20 minutes before first chemotherapy dose, and 2 hours before second chemotherapy dose found reductions in acute nausea (26.7% vs. 48.6%), and vomiting (13.3% vs. 33.3%).
Program details:
Lokesh KN, et al. Effects of immersive virtual reality for alleviating nausea and vomiting among patients receiving highly emetogenic chemotherapy: A randomized controlled trial. ESMO AI & Digital Oncology Congress 2026 - Abstract 141O
No comments:
Post a Comment